Humacyte Secures $1.475M Symvess Saudi Commitment, Raises $20M via Direct Offering
Humacyte obtained a binding purchase commitment of $1.475 million for Symvess to support clinical evaluation in Saudi hospitals under exclusive joint venture negotiations through July 2, 2026. It also priced a $20 million direct offering of 25 million shares to fund Symvess commercialization, BLA supplement filing and pipeline development.
1. Saudi Symvess Purchase Commitment
Humacyte secured a binding commitment to deliver at least $1.475 million of Symvess to hospitals in the Kingdom of Saudi Arabia to facilitate a clinical evaluation and healthcare provider training program.
2. Exclusive JV Negotiations
The company is in parallel talks with a KSA-based entity to establish a joint venture and licensing structure for Symvess commercialization, holding exclusive negotiation rights through July 2, 2026 while providing personnel to train medical professionals.
3. $20M Registered Direct Offering
Humacyte entered into a securities purchase agreement to sell 25 million common shares in a registered direct offering, generating $20 million in gross proceeds before expenses with closing expected around March 20, 2026.
4. Strategic Funding and Commercialization Plans
Net proceeds will fund the commercial launch of Symvess in vascular trauma, a BLA supplement filing for hemodialysis, ongoing Phase 3 trial read-out preparation and broader pipeline development and general corporate needs.